- HOME >
- GRADUATE >
- Human Sciences >
Obstetrics and Gynecology
| Master's Program | Human Sciences, Graduate School of Medicine |
|---|---|
| Doctor's Program | Medical Science Division, Department of Medical Science, Graduate School of Medicine, Science and Technology |
| Professor | SHIOZAWA Tanri |
|---|---|
| Associate Professor | MIYAMOTO Tsutomu |
| Senior Assistant Professor | KIKUCHI Norihiko |
| Assistant Professor | KOBARA Hisanori, ANDO Hirofumi, YAMADA Yasushi, IDA Koichi, HIGUCHI Shotaro |
E-mail ： ifujin(at)shinshu-u.ac.jp
※ Change (at) to @ when you send an e-mail.
Obstetrics and Gynecology (ObGyn) encompasses 4 major academic fields: Obstetrics, Gynecologic Oncology, Reproductive Medicine, and Woman's healthcare (Fig. 1). ObGyn is the medical field that supports women throughout their lifetime, from birth to the end of life. The uterus and ovaries, which are specific to females, markedly change throughout their lifetime. Pregnancy and delivery are the most dramatic changes, in which normal and abnormal conditions may sequentially occur. We want to obtain a clearer understanding of these changes and diseases specific to women and also perform medical examinations using not only ObGyn, but also, for example, embryology, pathology, and diagnostic imaging.
Although medical technologies have rapidly advanced, many issues have yet to be resolved. Among gynecologic cancers, the morbidity and mortality of endometrial and ovarian cancers are rapidly increasing in Japan. Therefore, the mechanisms underlying endometrial and ovarian carcinogenesis/progression need to be elucidated and new treatment and preventive methods developed based on these mechanisms. Due to advances in perinatal medicine, Japan has become the safest country for pregnancy and delivery. However, the onset mechanisms of hypertensive disorders of pregnancy (HDP) and intrauterine growth restriction (IUGR), which markedly affect perinatal outcomes, remain unclear. Although advances in assisted reproductive technologies such as in vitro fertilization and embryo transfer (IVF-ET) have also been achieved, many issues, such as increases in the incidence of chromosomal abnormalities and malformations, have to be overcome in the future.
Each of our divisions are actively conducting research to address these issues.
Divisions:
1. Gynecologic Cancer Group
2. Placenta Group
3. Reproduction Group
1. Mvunta DH, Miyamoto T, Asaka R, Yamada Y, Ando H, Higuchi S, Ida K, Kashima H, Shiozawa T. SIRT1 Regulates the Chemoresistance and Invasiveness of Ovarian Carcinoma Cells. Transl Oncol. 2017; 10: 621-631.
2. Ando H, Miyamoto T, Kashima H, Higuchi S, Ida K, Mvunta DH, Shiozawa T. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6. Horm Cancer. 2017; 8: 257-267.
3. Yamada Y, Miyamoto T, Kashima H, Kobara H, Asaka R, Ando H, Higuchi S, Ida K, Shiozawa T. Lipocalin 2 attenuates iron-related oxidative stress and prolongs the survival of ovarian clear cell carcinoma cells by up-regulating the CD44 variant. Free Radic Res. 2016; 50: 414-425.
4. Asaka R, Miyamoto T, Yamada Y, Ando H, Mvunta DH, Kobara H, Shiozawa T. Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target. Lab Invest. 2015; 95:1363-1373.
5. Kobara H, Miyamoto T, Suzuki A, Asaka R, Yamada Y, Ishikawa K, Kikuchi N, Ohira S, Shiozawa T. Lipocalin2 enhances the matrix metalloproteinase-9 activity and invasion of extravillous trophoblasts under hypoxia. Placenta. 2013; 34: 1036-1043.
6. Fuseya C, Horiuchi A, Hayashi A, Suzuki A, Miyamoto T, Hayashi T, Shiozawa T. Involvement of pelvic inflammation-related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis. Hum Pathol. 2012; 43: 1964-1972.
7. Takatsu A, Shiozawa T, Miyamoto T, Kurosawa K, Kashima H, Yamada T, Kaku T, Mikami Y, Kiyokawa T, Tsuda H, Ishii K, Togashi K, Koyama T, Fujinaga Y, Kadoya M, Hashi A, Susumu N, Konishi I. Preoperative differential diagnosis of minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia of the uterine cervix: a multicenter study of clinicopathology and magnetic resonance imaging findings. Int J Gynecol Cancer. 2011; 21: 1287-1296.
8. Horiuchi A, Hayashi T, Kikuchi N, Hayashi A, Fuseya C, Shiozawa T, Konishi I. Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1α to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene. Int J Cancer. 2012; 131: 1755-1767.
9. Miyamoto T, Kashima H, Suzuki A, Kikuchi N, Konishi I, Seki N, Shiozawa T. Laser-captured microdissection-microarray analysis of the genes involved in endometrial carcinogenesis: stepwise up-regulation of lipocalin2 expression in normal and neoplastic endometria and its functional relevance. Hum Pathol. 2011; 42: 1265-1274.
10. Miyamoto T, Shiozawa T, Kashima H, Feng YZ, Suzuki A, Kurai M, Nikaido T, Konishi I. Estrogen up-regulates mismatch repair activity in normal and malignant endometrial glandular cells. Endocrinology. 2006; 147: 4863-4870.
11. Shiozawa T, Miyamoto T, Kashima H, Nakayama K, Nikaido T, Konishi I. Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene. 2004; 23: 8603-8610.
